Clinical Trial Update: Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial investigating double-dose ranibizumab for polypoidal choroidal vasculopathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Polypoidal Choroidal Vasculopathy | Phase 2, Phase 3 | Status: TERMINATED